NICE Recommends Roche’s Tecentriq to NHS for NonSmall-Cell Lung Cancer

The UK’s National Institute for Health and Care Excellence (NICE) has recommended that the National Health Service (NHS) offer Roche’s immunotherapy Tecentriq (atezolizumab) for patients with untreated metastatic nonsmall-cell lung cancer.

The drug is authorized in the UK for patients whose tumors have PD-L1 expression on at least 50 percent of tumor cells or on 10 percent of tumor-infiltrating immune cells, or for individuals whose tumors do not contain epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutations.

The drug’s UK list price is approximately $5,387.50 per 20 mL vial, but NICE negotiated a confidential discounted price on behalf of the NHS.